^
Association details:
| Biomarker: | FGFR2 P253R |
|---|---|
| Cancer: | Tongue Carcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma
Excerpt:
An oral squamous cell carcinoma patient harboring a somatic FGFR2 P253R mutation demonstrates a partial response to an FGFR inhibitor….The patient was diagnosed with locally advanced (T2N1M0, stage III) squamous cell carcinoma of the right tongue in 2008 at the age of 52...multiple courses of chemotherapy including carboplatin, paclitaxel, cisplatin and cetuximab. In 2012, he had further progression in the right neck and left axilla.
Secondary therapy:
cisplatin + carboplatin + paclitaxel
DOI:
10.1158/0008-5472.CAN-12-3950
